Drug, enzyme and peptide delivery using erythrocytes as carriers.
about
Recent advancements in erythrocytes, platelets, and albumin as delivery systemsDrug-loaded erythrocytes: on the road toward marketing approvalImproving cell-based therapies by nanomodificationCell or cell membrane-based drug delivery systemsMacrophage depletion by free bisphosphonates and zoledronate-loaded red blood cellsIntegration of biosensors and drug delivery technologies for early detection and chronic management of illnessTumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.Targeted thrombolysis strategies for neuroprotective effectDrug-loaded sickle cells programmed ex vivo for delayed hemolysis target hypoxic tumor microvessels and augment tumor drug delivery.Encapsulation of FITC to monitor extracellular pH: a step towards the development of red blood cells as circulating blood analyte biosensorsCell permeable cocaine esterases constructed by chemical conjugation and genetic recombination.Erythrocyte membrane based cationic polymer-mcDNA complexes as an efficient gene delivery system.In vitro and in vivo degradation of Abeta peptide by peptidases coupled to erythrocytes.Recent advances in delivery systems for anti-HIV1 therapy.DNA aptamer-mediated cell targetingL-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL).Biomimetic proteolipid vesicles for targeting inflamed tissuesCell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application.Cell-based drug-delivery platforms.Carrier erythrocytes: recent advances, present status, current trends and future horizons.Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood.A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.Multifunctional theranostic red blood cells for magnetic-field-enhanced in vivo combination therapy of cancer.Enzyme-functionalized biomimetic apatites: concept and perspectives in view of innovative medical approaches.Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites.Doxorubicin-loaded platelets conjugated with anti-CD22 mAbs: a novel targeted delivery system for lymphoma treatment with cardiopulmonary avoidance.Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.Characterization of human erythrocytes as potential carrier for pravastatin: an in vitro study.Engineering erythrocytes as a novel carrier for the targeted delivery of the anticancer drug paclitaxelEncapsulation and in vitro evaluation of amikacin-loaded erythrocytes.Simulation of the osmosis-based drug encapsulation in erythrocytes.Biomembranes from slaughterhouse blood erythrocytes as prolonged release systems for dexamethasone sodium phosphate.Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery.Converting Red Blood Cells to Efficient Microreactors for Blood Detoxification.Application of Controlled Shear Stresses on the Erythrocyte Membrane as a New Approach to Promote Molecule Encapsulation.Can red blood cells prove to be a useful tool in tumor immunotherapy?Preparation and in-vitro characterization of tramadol-loaded carrier erythrocytes for long-term intravenous delivery.Erythrocyte-mediated delivery of pravastatin: In Vitro study of effect of hypotonic lysis on biochemical parameters and loading efficiency
P2860
Q26747764-232A6A28-9B81-4B33-826B-0C1F8A57AE4BQ26765322-137F1967-4AEB-40D0-B586-F0C7C83D2390Q28080427-7E318939-D279-4C49-81C8-586B36A87B51Q28080710-ED7065B8-55AB-4934-B1C3-C10A75BEA8EFQ28540086-10150A8C-6A01-4436-9421-9B227CB461EEQ30451853-374EEFC2-C710-42AB-9900-099B9BB69477Q33325343-05E5F541-343B-4435-B50D-CF146B809FCDQ34163191-60CC6DC1-E0A5-4C9C-B0CA-BD7086277EFAQ34170303-6912131E-22A1-45A0-9C3A-249D9E4BB65EQ35088949-16445944-930C-4243-BD31-F901E689D53CQ35952119-2D4296C0-EAE7-4F2F-B46F-5EEF6702F3D2Q36205158-4EC7C648-4BAE-45A1-897E-F54F01B734B9Q36291634-FC24CD5E-9F49-4ADF-837F-863226FFB709Q36761854-31C7546A-5325-4188-91D7-DD5A4619DBAAQ37222769-E3E44E9F-85C4-41D7-904A-C341882E96BFQ37371369-52FFD843-0DE2-4F5C-B8C6-53F9F90A10C0Q37451394-B1B8B234-7934-4B15-A92E-8F27EB979441Q37612333-2EA1285B-89DD-468A-934F-247AC19B324FQ38029631-0660FD9E-F411-4A37-9072-03259DB7D7DCQ38181182-73084B51-FACC-4AE1-955E-02612AF8A65CQ38387142-1C004BB8-1BCD-4760-9C11-9F45199E839BQ38409519-81B1E3A3-42EE-446A-BFD1-9AE2D3CB1393Q38994042-3C4317B2-C902-4ED0-95DF-5A3AA52908B6Q39060349-04808EC7-BC2A-43F0-988E-0218C8BE117EQ39693423-32DA600B-17F7-46AB-AAA2-238A900027EAQ41709540-C1BE4977-1F6E-48DC-B3AC-81915A7B1329Q42028534-EA20575D-A193-4E02-AFE9-FC8710341416Q42705033-DD11F9B5-E14D-4154-A139-40FA70E6BE94Q42736840-8313C898-5A64-4F4F-886F-B06852C478D7Q46777954-A8AF3054-9777-4D44-9C38-C87C887A6F6EQ47656459-E070A302-FCC0-4FB9-A39F-201703433A08Q47780316-18B87F65-B5C3-4529-B5A4-0CA9ABE8978AQ49788067-39E454C0-0D9A-4CF9-91E9-654ABDEEDFEFQ50222619-1E8D52C2-F585-4A89-B398-50C1DDE85054Q50265707-CBC6941D-921F-4C19-ADA5-ADE0C1449C62Q50502250-6D81BD39-E206-462A-99B8-D21C966EC527Q51548972-4D2A7CBE-EEA1-493B-9579-EE5B4FD2C4DEQ57535192-D74FBD41-0450-410A-A89C-98D288F35992
P2860
Drug, enzyme and peptide delivery using erythrocytes as carriers.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Drug, enzyme and peptide delivery using erythrocytes as carriers.
@ast
Drug, enzyme and peptide delivery using erythrocytes as carriers.
@en
type
label
Drug, enzyme and peptide delivery using erythrocytes as carriers.
@ast
Drug, enzyme and peptide delivery using erythrocytes as carriers.
@en
prefLabel
Drug, enzyme and peptide delivery using erythrocytes as carriers.
@ast
Drug, enzyme and peptide delivery using erythrocytes as carriers.
@en
P2093
P1476
Drug, enzyme and peptide delivery using erythrocytes as carriers.
@en
P2093
Aránzazu Zarzuelo Castañeda
Carmen Gutiérrez Millán
José M Lanao
María Luisa Sayalero Marinero
P356
10.1016/J.JCONREL.2003.11.018
P407
P577
2004-02-01T00:00:00Z